CMRX250117P4000
- 0.90
- -0.25-21.74%
Chimerix Newsroom
Is Chimerix (NASDAQ:CMRX) In A Good Position To Invest In Growth?
H.C. Wainwright Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $11
Express News | HC Wainwright & Co. Reiterates Buy on Chimerix, Maintains $11 Price Target
Chimerix Analyst Ratings
Edward White's Buy Rating on Chimerix Driven by Promising Clinical Data and Strategic NDA Plans
CervoMed CRVO Phase 2b Fails; Chimerix SNDA Application
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Sector Update: Health Care Stocks Decline Late Afternoon
Sector Update: Health Care
Top Midday Gainers
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings
Chimerix Price Target Raised to $7 From $5 at JonesResearch
Chimerix CMRX NDA Plans; UniQure QURE Accelerated Approval Path
Dow Falls 150 Points; Oracle Posts Downbeat Results
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?
Wall Street Set to Open Flat Tuesday as Investors Await Inflation Data
TD Cowen Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $8
Investors Look Ahead to Key Inflation Data as US Futures Tread Water in Tuesday's Premarket
TD Cowen Reaffirms Their Buy Rating on Chimerix (CMRX)
Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket